As clinical development grows increasingly complex, the industry has recognized the critical role of centralized processes and risk‑based monitoring in ensuring high‑quality, reliable data. Regulatory ...

Please provide your email address to receive an email when new articles are posted on . Care for COPD has consisted of combinations of previously used drugs for decades. Ensifentrine represents a ...

A new multidisciplinary study conducted by researchers at the University of Rochester Medical Center has found that the co-development of three systems, the gut microbiome, respiratory system and ...

A new multidisciplinary study conducted by researchers at the University of Rochester Medical Center has found that the co-development of three systems, the gut microbiome, respiratory system and ...

In early April, Pfizer announced a $525 million acquisition of ReViral’s novel therapy for respiratory syncytial virus (RSV). Since then, RSV therapies have garnered renewed global attention. However, ...

In a recent study published in Cytokine & Growth Factor Reviews, researchers discussed the development of messenger ribonucleic acid (mRNA) vaccines against the respiratory syncytial virus (RSV).

MELBOURNE, Australia, Jan. 28, 2025 (GLOBE NEWSWIRE) -- ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense immune enhancers to minimize the impact of ...

-- ENA-001 is currently in development for: post-operative respiratory depression, community drug overdose, and Apnea of Prematurity -- -- Approval for post-operative respiratory depression expected ...

Advent Therapeutics is developing vitamin A therapies aimed at preventing chronic lung disease in premature babies.

While adults have dominated long COVID headlines, a growing body of research is revealing that teenagers are experiencing persistent lung damage that’s fundamentally different from what we see in ...